NDC 83939-0022-01 - Oxybutynin Chloride
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 83939-0022
- Requested NDC
- 83939-0022-01
- Package NDCs from labels
- 83939-0022-1, 83939-0022-2, 83939-0022-3, 83939-0022-01
- Manufacturer
- VERITYRX, LLC
- Effective date
- 2025-10-31
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Oxybutynin Chloride - VERITYRX, LLC | VERITYRX, LLC | 2025-10-31 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 83939-0022-1 | Oxybutynin Chloride | 1 in 1 POUCH | TABLET | 1 | 1 | |
| 83939-0022-2 | Oxybutynin Chloride | 1 in 1 POUCH | TABLET | 1 | 1 | |
| 83939-0022-2 | Oxybutynin Chloride | 50 in 1 BOX, UNIT-DOSE | TABLET | 50 | 1 | |
| 83939-0022-3 | Oxybutynin Chloride | 1 in 1 POUCH | TABLET | 1 | 1 | |
| 83939-0022-3 | Oxybutynin Chloride | 100 in 1 BOX, UNIT-DOSE | TABLET | 100 | 1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | Coupler LLC | 3f7dc283-b168-8251-e063-6294a90a45a2 | 2025-12-24 | Warnings, Adverse reactions | L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | Coupler LLC | 3f7da2a3-ca46-d3e8-e063-6294a90abef3 | 2025-12-24 | Warnings, Adverse reactions | L9F3D9RENQ |
| oxybutynin chloride | OXYBUTYNIN CHLORIDE | Chartwell RX, LLC | e464c8dd-5222-4a6b-b7e9-ca608a403c6e | 2025-12-22 | Warnings, Adverse reactions | L9F3D9RENQ |
| oxybutynin chloride | OXYBUTYNIN CHLORIDE | Accord Healthcare, Inc. | 61496a1e-17bf-4f45-a20c-5bb98fe545ee | 2025-12-16 | Warnings, Adverse reactions | L9F3D9RENQ |
| Oxybutynin Chloride Extended Release | OXYBUTYNIN CHLORIDE | AvKARE | 94471401-a516-0fe7-ec9c-447dd2bee972 | 2025-12-16 | Warnings, Adverse reactions | L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | Upsher-Smith Laboratories, LLC | 3ee6835a-7a7d-49a9-8460-2f1dd270ead3 | 2025-12-11 | Warnings, Adverse reactions | 863664 L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | Ajanta Pharma USA Inc. | 95c2a144-ba0d-4011-ae0f-0e0ca876e8a8 | 2025-11-30 | Warnings, Adverse reactions | L9F3D9RENQ |
| OXYBUTYNIN CHLORIDE | OXYBUTYNIN CHLORIDE | A-S Medication Solutions | 44990ed6-b8e7-40f5-b636-e848024ec6d8 | 2025-11-18 | Warnings, Adverse reactions | 863664 L9F3D9RENQ |
| OXYBUTYNIN CHLORIDE | OXYBUTYNIN CHLORIDE | A-S Medication Solutions | 0697b3cf-b146-47c0-b5a5-5905ae8d1c97 | 2025-11-18 | Warnings, Adverse reactions | 863664 L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | VERITYRX, LLC | 427b6ffb-3ff4-932f-e063-6394a90ae8b9 | 2025-10-31 | Warnings, Adverse reactions | ANDA209823 83939-0022-3 83939-0022-2 83939-0022-1 83939-0022 83939002201 863664 427b8d8e-0187-6ba0-e063-6294a90ac52b 427b6ffb-3ff4-932f-e063-6394a90ae8b9 L9F3D9RENQ |
| Oxybutynin Chloride Extended Release | OXYBUTYNIN CHLORIDE | PD-Rx Pharmaceuticals, Inc. | b5653b7e-1e3b-4da3-b3a2-33318f448c67 | 2025-10-20 | Warnings, Adverse reactions | L9F3D9RENQ |
| Oxybutynin Chloride Extended Release | OXYBUTYNIN CHLORIDE | PD-Rx Pharmaceuticals, Inc. | e466d963-469a-4b1c-87f9-2e3e1e9bdf3d | 2025-10-02 | Warnings, Adverse reactions | L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | Major Pharmaceuticals | 7769ad3d-6228-4b2d-8f44-4efe990d3fad | 2025-09-19 | Warnings, Adverse reactions | ANDA209823 863664 L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | Cardinal Health 107, LLC | 8455b543-81ce-4522-ae9b-8396f944945c | 2025-08-18 | Warnings, Adverse reactions | ANDA209823 863664 L9F3D9RENQ |
| OXYBUTYNIN CHLORIDE | OXYBUTYNIN CHLORIDE | PD-Rx Pharmaceuticals, Inc. | 8bd5dce0-d56a-4e64-8de7-e7cd7775526b | 2025-08-18 | Warnings, Adverse reactions | 863664 L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | Major Pharmaceuticals | 7688cce8-797d-454c-95fb-52689741582e | 2025-07-15 | Warnings, Adverse reactions | L9F3D9RENQ |
| Oxybutynin Chloride Extended Release | OXYBUTYNIN CHLORIDE | Rising Pharma Holdings, Inc. | ab431781-3183-4638-b656-f40a61f07940 | 2025-05-19 | Warnings, Adverse reactions | L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | AvKARE | 3418ca19-feb0-9821-e063-6394a90ae819 | 2025-05-01 | Warnings, Adverse reactions | 863664 L9F3D9RENQ |
| Oxybutynin Chloride Extended Release | OXYBUTYNIN CHLORIDE | AvPAK | 242b4766-bc2b-0073-d72d-1bf879bbee24 | 2025-04-17 | Warnings, Adverse reactions | L9F3D9RENQ |
| Oxybutynin Chloride | OXYBUTYNIN CHLORIDE | PD-Rx Pharmaceuticals, Inc. | 9c8ced4b-94de-4df8-bea3-b42b8846b769 | 2025-03-12 | Warnings, Adverse reactions | 863664 L9F3D9RENQ |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.